dermatology
Autoimmune diseases

News In Brief: Pemphigus biosimilar safety; Biologic approved for PsA; New melanoma treatment benchmark

Biosimilar equivalence questioned for pemphigus treatment Dermatologists in NSW have questioned whether rituximab biosimilars can be assumed to be equivalent for pemphigus vulgaris after five patients of their patients developed adverse infusion reactions when Riximyo was substituted for the originator Mabthera. Dr Genevieve Ho and colleagues at St George Hospital, Sydney, said the switches were ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic